Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04827745 · ClinicalTrials.gov registry record · Phase 2
Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL
A Phase 2 study of Mixed Phenotype Acute Leukemia (MPAL) and Measurable Residual Disease (MRD), sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT04827745 is a Phase 2 study of Mixed Phenotype Acute Leukemia (MPAL) and Measurable Residual Disease (MRD) that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 2 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04827745, a Phase 2 study of Mixed Phenotype Acute Leukemia (MPAL) and Measurable Residual Disease (MRD), has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a research study to find out if a drug called blinatumomab is effective for treating patients with relapsed or refractory (R/R) or measurable residual disease (MRD) CD19-positive mixed phenotypic acute leukemia (MPAL). Measurable Residual Disease (MRD) means that there are a small number of cancer cells remaining after treatment
Conditions Studied
Interventions
- DRUG BLINCYTO (Blinatumomab)
Study Locations (1)
Maryland
- Greenebaum Cancer Center at University of Maryland Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-06-11 |
| Est. Completion | 2025-05-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04827745
The ClinicalTrials.gov registry entry for NCT04827745 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mixed Phenotype Acute Leukemia (MPAL) appearing as the primary indexed condition, and to 1 intervention - of which BLINCYTO (Blinatumomab) is the first listed.
NCT04827745 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04827745 about?
NCT04827745 is a clinical study titled "Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL". This is a research study to find out if a drug called blinatumomab is effective for treating patients with relapsed or refractory (R/R) or measurable residual disease (MRD) CD19-positive mixed phenotypic acute leukemia (MPAL). Measurable Residual Disease (MRD) means that there are a small number of ...
What is the current status of trial NCT04827745?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2021-06-11. Estimated completion is 2025-05-22.
What conditions does trial NCT04827745 study?
This clinical trial studies the following conditions: Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD).
What interventions are being tested in trial NCT04827745?
The interventions under investigation include: BLINCYTO (Blinatumomab) (DRUG).
Who is sponsoring clinical trial NCT04827745?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04827745 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mixed Phenotype Acute Leukemia (MPAL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Mixed Phenotype Acute Leukemia (MPAL)
All registered trials for this condition
Measurable Residual Disease (MRD)
All registered trials for this condition
Maryland
All trials with a study site in Maryland
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.